Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Moderna, Inc.    MRNA


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Moderna on track to report late-stage COVID-19 vaccine data next month

10/29/2020 | 10:18am EST
FILE PHOTO: Moderna Therapeutics seen during COVID-19 in Massachusetts

(Reuters) - Moderna Inc on Thursday said it is on track to report early data from a late-stage trial of its experimental COVID-19 vaccine next month, offering the clearest timeline yet for when the world will know whether it is effective.

The company, one of the front-runners in the global race to produce vaccines to protect against COVID-19, said an independent data monitoring committee is expected to conduct an interim review of its ongoing 30,000-person trial in November. Its shares rose 3%.

The company said it is preparing to distribute the vaccine, known as mRNA-1273, and expects to be able to produce 20 million doses by the end of the year, and between 500 million and 1 billion in 2021.

Moderna said infection rates in the trial were on track with expectations.

"Since we are following the ZIP codes (U.S. geographic areas) and the counties from which these participants come, we have pretty sophisticated models of what to expect, and I think we're on track for those expectations," Chief Medical Officer Tal Zaks said.

A U.S. regulatory greenlight for Moderna's vaccine would be a major endorsement of the biotech's vaccine platform, Chief Executive Stephane Bancel said during the company's quarterly results conference call.

The Moderna vaccine uses synthetic messenger RNA (mRNA) to mimic the surface of the coronavirus and teach the immune system to recognize and neutralize it. The technology, which has yet to produce an approved vaccine, is also used in the COVID-19 vaccine being developed by Pfizer Inc and German partner BioNTech SE.

Moderna said it expects two-month follow-up safety data, as required by the U.S. Food and Drug Administration, in the second half of November, after which it will file for an emergency use authorization. Recent FDA guidelines called on COVID-19 vaccine developers to watch trial subjects for two months after they receive a final dose for any side effects that may crop up.

The Cambridge, Massachusetts-based company has signed supply deals with the U.S. government and several other countries, and is also in talks with the World Health Organization-led group, COVAX, about vaccine distribution and a tiered pricing proposal.

Moderna said its deal with the U.S. government for 100 million doses values the vaccine at $25 per dose, based on the grants it received and performance payments. The U.S. government has an option to buy an additional 400 million doses.

The company, whose supply agreements include deals with Japan, Canada and Israel, said it is in talks with the European Union and others.

Other vaccine in final stages of human testing include those from Pfizer, AstraZeneca Plc and Johnson & Johnson.

Pfizer said this week that there had not yet been enough infections in its 44,000-volunteer trial to trigger the first analysis of whether its vaccine works.

(Reporting by Manas Mishra and Manojna Maddipatla in Bengaluru and Carl O'Donnell in New York; Editing by Saumyadeb Chakrabarty and Bill Berkrot)

By Manas Mishra and Carl O'Donnell

© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC -1.36% 7884 Delayed Quote.5.17%
BIONTECH SE -4.35% 101.87 Delayed Quote.200.68%
MODERNA, INC. -2.44% 98.56 Delayed Quote.403.89%
PFIZER INC. 0.22% 36.6 Delayed Quote.-6.59%
All news about MODERNA, INC.
06:50aMODERNA : Announces the European Commission's Approval of Advance Purchase Agree..
06:39aMODERNA : EU eyes tougher measures against foreign industrial espionage
06:06aEXPLAINER : When and how will COVID-19 vaccines become available?
05:15aUPDATED : Top Employer COVID Vaccine Questions And Answers
04:30aRECIPHARM : to produce some of Moderna's COVID-19 vaccine in France
02:37aFLIRTING WITH RECORD HIGHS : European stocks back to normal in 2021 - Reuters po..
11/24ANALYSIS : Dow cracks 30,000, a psychological boost during a pandemic
11/24Retailers already fear U.S. holiday 'shipageddon'; now here come vaccines
11/24Ford orders 12 ultra-cold freezers to distribute COVID-19 vaccines to employe..
11/24Oil closes at highest level since March on vaccine trials, Biden transition
More news
Financials (USD)
Sales 2020 432 M - -
Net income 2020 -673 M - -
Net cash 2020 2 945 M - -
P/E ratio 2020 -68,3x
Yield 2020 -
Capitalization 39 001 M 39 001 M -
EV / Sales 2020 83,4x
EV / Sales 2021 6,11x
Nbr of Employees 1 100
Free-Float 90,0%
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 17
Average target price 104,35 $
Last Close Price 98,56 $
Spread / Highest target 68,4%
Spread / Average Target 5,88%
Spread / Lowest Target -39,1%
EPS Revisions
Stéphane Bancel Chief Executive Officer & Director
Stephen Hoge President
Noubar B. Afeyan Chairman
David W. Meline Chief Financial Officer
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capitalization (M$)
MODERNA, INC.403.89%39 001
LONZA GROUP AG56.17%44 950
CELLTRION, INC.66.57%36 284
SEAGEN INC.44.08%29 684
IMMUNOMEDICS, INC.315.22%20 324